The report assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the pulmonary embolism diagnostics market has also been forecasted for the period 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Cyclopharm, Philips, Siemens and Jubilant LifeSciences Limited are some of the key players featured in this report.
- Advertising -
Research By Markets adds "Pulmonary Embolism Diagnostic Mark…casts (2017-2021)" to its online repository. The report provides an in-depth analysis of the developed region pulmonary embolism diagnostic market by value, by volume (number of patients), by segments,.
The report provides an analysis of the developed regions such as Canada, Australia and Europe on the basis of diagnostics penetration and the regions such as the US with an addressable market opportunity for the diagnostics penetration.
The competition in the pulmonary embolism diagnostic market, especially V/Q scan is dominated by one big player at global level, Cyclopharm and at regional level, in the US, the competition is dominated by Lantheus Holdings, Inc.
- Advertising -
Further, key players of the Global Pulmonary Thromboembolism Diagnostic Market Cyclopharm, Philips, Siemens and Jubilant LifeSciences Limited are also profiled with their financial information and respective business strategies.
Access to this Report: www.researchbymarkets.com/report/p…17-2021-4972.html
Venous Thromboembolism (VTE) is a type of blood clot that starts in the vein. Most commonly VTE starts in the legs of the patient, however, it could occur in any other part of the body also.
There are two types of VTE: Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE).
The pulmonary embolism generally occurs due to DVTs or pelvic vein thrombosis.
Pulmonary embolism is a condition where the clot that is formed deep into the veins of the patient legs (or in any other body part) breaks off and travels through the bloodstream to the lungs. The clot has a tendency to block a blood vessel in the lungs and hence damage them.
Pulmonary embolism is not a disease rather it is a complication of underlying VTE. There are several risk factors for pulmonary embolism such as cancer, obesity, sedentary lifestyle, age factor, major surgery, genetic blood clotting disorder or fracture of the hip or leg,.
The onset of pulmonary embolism is depicted by shortness of breath, sudden chest pain and coughing blood. These symptoms are then followed by other symptoms such as flank pain, wheezing, cardiac murmur,.
Developed Regions (Canada, Europe, Australia and Parts of Asia)
United States of America
Jubilant LifeSciences Limited
- Increasing Global Incidence of Cancer
- Rising Global Population with Obesity
- Increasing Global Per-Capita Healthcare Expenditure
- Increasing Global Aging Population
- Increasing Global Oral Contraceptives Demand and Number of Pregnancies
- Introduction of Novel Oral Anticoagulants
- Prohibition of Technegas in the US
- Global Cigarette Consumption
- Mo99 Isotope Cost Savings for the End User
- Product Innovation
- Patent Expiration and Renewal
- Prolonged Hours of Sitting
- Ongoing Technological Advancement and Development
Key Topics Covered:
- Executive Summary
- Developed Region Market Analysis
- Regional Market Analysis
- Market Dynamics
- Competitive Landscape
- Company Profiling
Category: Market Research Publishers and RetailersCompany profile: Research by Markets is an online Market Research Report Repository. Our repository contains reports segmented by Geography and Industry. We cover all major Industry Verticals - Information Technology, Semiconductor, Electronics, Manufacturing, Food & Beverages, Telecommunications, Healthcare, Pharmaceutical, Automotive, BioTechnology, Energy & Power, Banking and many more. We have dedicated Account Managers for Corporate Clients to ensure seamless customer support. Corporates can als ...
For more information: